# A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1

> **NCT03681184** · PHASE3 · COMPLETED · sponsor: **Alnylam Pharmaceuticals** · enrollment: 39 (actual)

## Conditions studied

- Primary Hyperoxaluria Type 1 (PH1)

## Interventions

- **DRUG:** Placebo
- **DRUG:** Lumasiran

## Key facts

- **NCT ID:** NCT03681184
- **Lead sponsor:** Alnylam Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-27
- **Primary completion:** 2019-11-05
- **Final completion:** 2024-01-12
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2024-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03681184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03681184, "A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03681184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*